• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

    12/9/24 4:04:43 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETON alert in real time by email
    SC 13G 1 eton13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

    Eton Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    29772L108

    (CUSIP Number)

    December 2, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 29772L108

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 1,397,669
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 1,397,669

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,397,669

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.4%

     

    12.Type of Reporting Person (See Instructions) OO, IA

     2 
    CUSIP No. 29772L108

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 1,397,669
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 1,397,669

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,397,669

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.4%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

     3 
    CUSIP No. 29772L108

     

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power -0-

     

    6. Shared Voting Power 1,315,117
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 1,315,117

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,315,117

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.1%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     4 
    CUSIP No. 29772L108

     

    Item1.
    (a)Name of Issuer

    Eton Pharmaceuticals, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    21925 W. Field Parkway, Suite 235, Deer Park, IL 60010-7278

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, par value $0.001 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 29772L108.
     5 
    CUSIP No. 29772L108

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 25,836,204 shares of Common Stock outstanding as October 31, 2024, as reported in the Form 10-Q filed by the Issuer on November 12, 2024.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of EcoR1 and Mr. Nodelman:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Qualified Fund:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     6 
    CUSIP No. 29772L108

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: December 9, 2024

     

    EcoR1 CAPITAL, LLC

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
     7 
    CUSIP No. 29772L108

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: December 9, 2024

    EcoR1 CAPITAL, LLC

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

    08689\007\10534720.v1

    Get the next $ETON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETON

    DatePrice TargetRatingAnalyst
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    1/10/2025$21.00Buy
    B. Riley Securities
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    9/4/2024$9.00Buy
    H.C. Wainwright
    5/6/2024$8.00Buy
    Craig Hallum
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $ETON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

    DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has

    8/20/25 6:50:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growthQ2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 millionLaunched KHINDIVI™ (hydrocortisone) Oral SolutionReached 100 active INCRELEX® patients, ahead of previous guidance of year endCompany projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidanceManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative phar

    8/7/25 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In:        (800) 715-9871 or (646) 307-1963; Conference ID: 5899895 Webcast:      Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. In

    7/28/25 7:00:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/12/25 4:32:51 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    10/25/24 4:05:24 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    10/8/24 6:34:32 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gruber James R. sold $673,714 worth of shares (41,713 units at $16.15), decreasing direct ownership by 16% to 204,753 units (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    8/20/25 5:14:03 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Krempa David sold $504,318 worth of shares (34,000 units at $14.83), decreasing direct ownership by 5% to 612,646 units (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/16/25 4:56:08 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/12/25 4:32:51 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

    H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $33.00 from $17.00 previously

    1/23/25 9:02:14 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Eton Pharmaceuticals with a new price target

    B. Riley Securities initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $21.00

    1/10/25 7:49:32 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

    H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $15.00 previously

    1/6/25 8:01:16 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    SEC Filings

    View All

    SEC Form 10-Q filed by Eton Pharmaceuticals Inc.

    10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    8/7/25 4:23:04 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    8/7/25 4:17:59 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    7/8/25 7:10:10 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Financials

    Live finance-specific insights

    View All

    Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growthQ2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 millionLaunched KHINDIVI™ (hydrocortisone) Oral SolutionReached 100 active INCRELEX® patients, ahead of previous guidance of year endCompany projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidanceManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative phar

    8/7/25 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In:        (800) 715-9871 or (646) 307-1963; Conference ID: 5899895 Webcast:      Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. In

    7/28/25 7:00:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

    Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 millionRelaunched pediatric endocrinology biologic INCRELEX® in the U.S. and out-licensed international rightsEstablished Wilson disease franchise with the acquisition and relaunch of GALZIN® (zinc acetate) capsules and the introduction of product candidate ET-700Announced positive pivotal clinical study results for ET-600 and submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration

    5/13/25 4:01:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Leadership Updates

    Live Leadership Updates

    View All

    Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

    Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical

    12/3/24 6:50:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

    DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we

    4/11/22 4:01:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

    LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex

    11/18/21 2:04:01 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

    SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    12/9/24 4:04:43 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eton Pharmaceuticals Inc.

    SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    9/12/24 4:05:13 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Eton Pharmaceuticals Inc. (Amendment)

    SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    4/30/24 7:00:15 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care